Matthew D. Galsky, MD, discusses how urologists should approach patient selection for perioperative durvalumab plus chemotherapy based on eligibility criteria for the NIAGARA trial. The FDA approved ...

The AUA Annual Meeting will cover bladder cancer, prostate cancer, sexual health, and BPH, featuring practice-changing sessions and clinical trials. Interviews with experts will discuss new guidelines ...

Low baseline IsoPSA index correlates with reduced risk of clinically significant prostate cancer in patients with elevated PSA levels. Patients with low IsoPSA index showed lower rates of prostate ...

SunRISe-5 and MoonRISe-1 trials investigate TAR-200 and TAR-210 in non-muscle-invasive bladder cancer, focusing on disease-free survival and recurrence prevention. ARASTEP trial evaluates darolutamide ...

Video content above is prompted by the following: Evolution of BPH Treatment Outcomes Dr Christopher Kelly discusses the evolution of patient outcomes with different benign prostatic hyperplasia (BPH) ...

Testicular cancer cure rates have improved, but challenges in recurrence prediction and quality of life management persist. Emerging biomarkers, such as miR-371a-3p, show promise in improving ...

The release of the first overactive bladder (OAB) guidelines was associated with an increase in OAB diagnoses, a decrease in anticholinergic medication use, and a rise in beta-3 agonist use, according ...

The PRELUDE trial is assessing oncological outcomes with neoadjuvant 177Lu-PSMA-617 in high-risk, localized prostate cancer. 177 Lu-PSMA-617 (Pluvicto) was approved by the FDA in March 2022 for ...

UTUC affects 1-2 per 100,000 people in the U.S., representing 6% of urothelial carcinoma cases, with symptoms like hematuria and urinary obstruction. Treatment strategies for UTUC depend on tumor ...

The website is meant to educate patients and their caregivers on several aspects of the kidney cancer journey. Receiving an initial diagnosis of renal cell carcinoma (RCC) is often an overwhelming ...

We preview several noteworthy P2 presentations in the urologic oncology space. The American Urological Association (AUA) will try its luck in Las Vegas, Nevada for its 2025 annual meeting. Taking ...

Combination of BWL and ultrasonic propulsion effectively fragments and repositions small renal stones in awake patients without anesthesia. The procedure achieved a 71% success rate in reducing stone ...